These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9059793)

  • 21. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 22. Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's disease.
    Priori A; Foffani G; Pesenti A; Tamma F; Bianchi AM; Pellegrini M; Locatelli M; Moxon KA; Villani RM
    Exp Neurol; 2004 Oct; 189(2):369-79. PubMed ID: 15380487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased cortical inhibition induced by apomorphine in patients with Parkinson's disease.
    Manfredi L; Garavaglia P; Beretta S; Pellegrini G
    Neurophysiol Clin; 1998 Feb; 28(1):31-8. PubMed ID: 9562997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The next chapter in symptomatic Parkinson disease treatments.
    Hengartner D; Fernandez HH
    Parkinsonism Relat Disord; 2019 Feb; 59():39-48. PubMed ID: 30661840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Somatosensory evoked potentials in Parkinson's disease and vascular parkinsonism].
    Tachibana H; Takeda M; Narita M; Sugita M; Kondo J; Miyauchi M; Mimura K; Matsuoka A
    Rinsho Byori; 1987 Jun; 35(6):698-702. PubMed ID: 3669380
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Median nerve somatosensory evoked potentials. Apomorphine-induced transient potentiation of frontal components in Parkinson's disease and in parkinsonism.
    Rossini PM; Bassetti MA; Pasqualetti P
    Electroencephalogr Clin Neurophysiol; 1995 May; 96(3):236-47. PubMed ID: 7750449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.
    Lewis SJ; Slabosz A; Robbins TW; Barker RA; Owen AM
    Neuropsychologia; 2005; 43(6):823-32. PubMed ID: 15716155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvements in non-motor and motor fluctuations in parkinson's disease after intermittent apomorphine treatment.
    Erer S; Zarifoglu M
    Neurol India; 2017; 65(2):388-389. PubMed ID: 28290407
    [No Abstract]   [Full Text] [Related]  

  • 31. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of dopamine on semantic activation in Parkinson's disease: evidence from a multipriming task.
    Angwin AJ; Copland DA; Chenery HJ; Murdoch BE; Silburn PA
    Neuropsychology; 2006 May; 20(3):299-306. PubMed ID: 16719623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopaminergic modulation of cortico-cortical functional connectivity in Parkinson's disease: an MEG study.
    Stoffers D; Bosboom JL; Wolters ECh; Stam CJ; Berendse HW
    Exp Neurol; 2008 Sep; 213(1):191-5. PubMed ID: 18590728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurophysiology of sensorimotor integration in Parkinson's disease.
    Rossini PM; Filippi MM; Vernieri F
    Clin Neurosci; 1998; 5(2):121-30. PubMed ID: 10785838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subthalamic oscillatory activities at beta or higher frequency do not change after high-frequency DBS in Parkinson's disease.
    Foffani G; Ardolino G; Egidi M; Caputo E; Bossi B; Priori A
    Brain Res Bull; 2006 Mar; 69(2):123-30. PubMed ID: 16533660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
    Albanese A; Bonuccelli U; Brefel C; Chaudhuri KR; Colosimo C; Eichhorn T; Melamed E; Pollak P; Van Laar T; Zappia M
    Mov Disord; 2001 Mar; 16(2):197-201. PubMed ID: 11295770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amantadine sulfate infusion effect on N30 somatosensory evoked potentials in Parkinson's disease.
    Bostantjopoulou S; Katsarou Z; Georgiadis G; Zafiriou D; Kazis A
    Clin Neuropharmacol; 2002; 25(2):115-8. PubMed ID: 11981240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.
    Antonini A; Tolosa E
    Expert Rev Neurother; 2009 Jun; 9(6):859-67. PubMed ID: 19496689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.